Base de dados : MEDLINE
Pesquisa : C11.768.760 [Categoria DeCS]
Referências encontradas : 3590 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 359 ir para página                         

  1 / 3590 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505511
[Au] Autor:Grzybowski A; Elikowski W; Gaca-Wysocka M
[Ad] Endereço:Department of Ophthalmology, Poznan City Hospital, Poznan.
[Ti] Título:Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report.
[So] Source:Medicine (Baltimore);97(1):e9255, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: To analyze cardiovascular risk factors and comorbidity of acute unilateral visual loss due to combined central retinal vein occlusion (CRVO) and cilioretinal artery occlusion (CLRAO). PATIENT CONCERNS: Among patients with retinal vein or artery occlusion hospitalized at the Department of Ophthalmology between January 2011 and August 2017, subjects with combined CRVO/CLRAO were selected. All of them underwent ophthalmologic and cardiologic examination, including fluorescein angiography, optical coherence tomography, 12-lead electrocardiogram, transthoracic and transesophageal echocardiography, carotid Doppler sonography, cerebral magnetic resonance imaging, and a panel of laboratory tests. DIAGNOSES: Four subjects with coexisting CRVO and CLRAO were found among 146 patients with retinal vein or artery occlusion. There were no other types of concomitance of CRVO and retinal artery occlusion. INTERVENTIONS: All patients were treated with low molecular heparin in a full dose for 2 weeks, then with 1 mg/kg once daily for the next 2 weeks, followed by acetylsalicylic acid 75 mg/kg/d. Other medication included long-term statins, angiotensin-converting-enzyme inhibitor in 3 patients and beta-blocker in one patient. OUTCOMES: All patients with CRVO/CLRAO presented multiple cardiovascular risk factors, including hypertension, obesity, hyperlipidemia, chronic nicotine addiction, and a positive family history of coronary artery disease or stroke. In all of them, echocardiography revealed left ventricular hypertrophy and atherosclerotic lesions in the descending aorta; in addition, 3 patients had insignificant atherosclerotic plaques in the carotid artery. Also, in 3 subjects, focal ischemic cerebral changes were diagnosed. LESSONS: Patients with combined CRVO and CLRAO present numerous cardiovascular risk factors and abnormalities on imaging examinations, which should be routinely evaluated and treated.
[Mh] Termos MeSH primário: Oclusão da Artéria Retiniana/complicações
Oclusão da Veia Retiniana/complicações
Transtornos da Visão/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso de 80 Anos ou mais
Artérias Carótidas/diagnóstico por imagem
Pré-Escolar
Ecocardiografia Transesofagiana
Feminino
Seres Humanos
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Neuroimagem
Oclusão da Artéria Retiniana/diagnóstico por imagem
Oclusão da Veia Retiniana/diagnóstico por imagem
Fatores de Risco
Transtornos da Visão/diagnóstico por imagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009255


  2 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471106
[Au] Autor:Son BK; Kwak HW; Kim ES; Yu SY
[Ad] Endereço:Department of Ophthalmology, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, Korea.
[Ti] Título:Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.
[So] Source:Korean J Ophthalmol;31(3):209-216, 2017 Jun.
[Is] ISSN:2092-9382
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the effectiveness and safety of intravitreal ranibizumab compared with bevacizumab for the treatment of macular edema associated with branch retinal vein occlusion (BRVO). METHODS: This was a retrospective study of 80 eyes with macular edema associated with BRVO. Patients received either 0.5 mg of ranibizumab (n = 24) or 1.25 mg of bevacizumab (n = 56) intravitreally. Both groups received three initial monthly injections followed by as-needed injections. The best-corrected visual acuity, central subfield thickness, mean number of injections, and retreatment rate were evaluated monthly for 6 months after the initial injection. RESULTS: The best-corrected visual acuity significantly improved from logarithm of the minimal angle of resolution (logMAR) 0.55 ± 0.26 at baseline to 0.24 ± 0.26 at 6 months in the ranibizumab group (p < 0.001) and from logMAR 0.58 ± 0.21 at baseline to 0.29 ± 0.25 at 6 months in the bevacizumab group (p < 0.001), which is not a statistically significant difference (p = 0.770). The mean reduction in central subfield thickness at 6 months was 236 ± 164 µm in the ranibizumab group (p < 0.001) and 219 ± 161 µm in the bevacizumab group (p < 0.001), which is not also a statistically significant difference (p = 0.698). The mean numbers of ranibizumab and bevacizumab injections were 3.25 ± 0.53 and 3.30 ± 0.53, respectively (p = 0.602). In addition, after the three initial monthly injections, the retreatment rates for ranibizumab and bevacizumab injections were 20.8% and 26.7%, respectively (p = 0.573). CONCLUSIONS: Both ranibizumab and bevacizumab were effective for the treatment of BRVO and produced similar visual and anatomic outcomes. In addition, the mean number of injections and the retreatment rates were not significantly different between the groups.
[Mh] Termos MeSH primário: Bevacizumab/administração & dosagem
Edema Macular/tratamento farmacológico
Ranibizumab/administração & dosagem
Oclusão da Veia Retiniana/complicações
Acuidade Visual
[Mh] Termos MeSH secundário: Inibidores da Angiogênese/administração & dosagem
Relação Dose-Resposta a Droga
Feminino
Angiofluoresceinografia
Seguimentos
Fundo de Olho
Seres Humanos
Injeções Intravítreas
Macula Lutea/patologia
Edema Macular/diagnóstico
Edema Macular/etiologia
Masculino
Meia-Idade
Oclusão da Veia Retiniana/diagnóstico
Oclusão da Veia Retiniana/tratamento farmacológico
Estudos Retrospectivos
Fatores de Tempo
Tomografia de Coerência Óptica
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 2S9ZZM9Q9V (Bevacizumab); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.3341/kjo.2015.0158


  3 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29426292
[Au] Autor:Brogan K; Precup M; Rodger A; Young D; Gilmour DF
[Ad] Endereço:Glasgow Centre for Ophthalmic Research, Tennent Institute of Ophthalmology, Gartnavel General Hospital, Greater Glasgow and Clyde, Glasgow, UK. kerr.brogan@ggc.scot.nhs.uk.
[Ti] Título:Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.
[So] Source:BMC Ophthalmol;18(1):37, 2018 Feb 09.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Predicting how patients with central retinal vein occlusion (CRVO) will respond to intravitreal anti-VEGF is challenging. The purpose of this study was to identify pre-treatment clinical features in CRVO that predict visual acuity (VA) following intravitreal ranibizumab. METHODS: Medical records, fundus images and optical coherence tomography (OCT) scans of treatment naïve patients with CRVO receiving PRN intravitreal ranibizumab were retrospectively reviewed. Early Treatment Diabetic Retinopathy Study (ETDRS) VA and central retinal thickness (CRT) were recorded at baseline, 3 and 12 months after starting therapy. Regression analysis was used to determine independent predictors of VA at 3 and 12 months follow-up. Possible predictors included baseline VA, age, presence of cotton wool spots (CWS), haemorrhages (few scattered or multiple deep), foveal detachment, CRT, time from presentation to treatment, number of injections given, presence of RAPD, and cause of CRVO. RESULTS: Data from 52 eyes of 50 patients receiving intravitreal ranibizumab treatment for CRVO were analyzed. The mean pre-treatment VA was 43.3 (SD 22.5) letters, which improved to 52.0 (SD 24.3) letters at 3 months, then dropped to 42.0 (SD 30.26) at 12 months. Baseline CRT reduced from 616.7 µm (SD 272.4) to 346.0 µm (SD 205.2) at 3 months and 304.0 µm (SD 168.3) at 12 months. The following features were predictive of poorer VA after starting intravitreal ranibizumab: Poorer pretreatment VA (3-months, P = 0.010; 12-months, P = 0.006), increasing age (3-months, P = < 0.001; 12-months, P = 0.006), and presence of CWS (3-months, P < 0.001; 12-months, P = 0.045). CONCLUSION: Pre-treatment VA, older age, and presence of CWS are easily identifiable clinical features in the hospital setting which help predict visual outcome in patients with CRVO receiving intravitreal ranibizumab.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Ranibizumab/uso terapêutico
Oclusão da Veia Retiniana/diagnóstico por imagem
Tomografia de Coerência Óptica
Acuidade Visual/fisiologia
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Injeções Intravítreas
Masculino
Oclusão da Veia Retiniana/tratamento farmacológico
Oclusão da Veia Retiniana/fisiopatologia
Estudos Retrospectivos
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180211
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0701-x


  4 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29185099
[Au] Autor:Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
[Ad] Endereço:Department of Ophthalmology, Campus Virchow-Klinikum, Charité - University Medicine Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany. sibylle.winterhalter@charite.de.
[Ti] Título:Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
[So] Source:Graefes Arch Clin Exp Ophthalmol;256(2):267-279, 2018 Feb.
[Is] ISSN:1435-702X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the therapeutic outcome for dexamethasone implant (DEX) or intravitreal ranibizumab (IVR) injections over 6 months in patients with macular edema due to branch or central retinal vein occlusion (BRVO, CRVO), in a real-life setting. METHODS: A total of 107 patients with BRVO or CRVO were included into this retrospective single-center observational study. Patients were treated with monotherapy consisting of DEX or three monthly IVR injections following a pro re nata regimen (PRN). Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and intraocular pressure (IOP) were compared between the two therapy groups after 1, 3 and 6 months. RESULTS: BRVO patients treated with DEX achieved a statistically significant gain in BCVA measured in logMAR after 1 month (mean gain, 95% CI: 0.21, 0.08-0.34, p = 0.001), 3 months (0.16, 0.03-0.28, p = 0.012) and 6 months (0.19, 0.07-0.32, p = 0.002), whereas patients treated with IVR showed a statistically significant BCVA gain in month 3 (mean improvement, 95% CI: 0.13, 0.01-0.26, p = 0.039) and month 6 (0.16, 0.03-0.29, p = 0.018). BCVA in CRVO patients with DEX worsened slightly at month 6 (mean worsening, 95% CI: -0.08, -0.24 to 0.08, p = 0.305), while IVR treated-patients achieved a statistically significant BCVA gain at 3 months (mean improvement, 95% CI: 0.14, 0.02-0.25, p = 0.021). Both therapies were accompanied by statistically significant CRT reductions of 150 to 200 µm (median). Adverse events reported were predictable and limited. CONCLUSIONS: In a clinical setting, comparable improvement in BCVA and CRT were observed after DEX and IVR injections for treatment of BRVO. CRVO patients showed greater benefit with IVR.
[Mh] Termos MeSH primário: Dexametasona/administração & dosagem
Edema Macular/tratamento farmacológico
Ranibizumab/administração & dosagem
Oclusão da Veia Retiniana/tratamento farmacológico
Acuidade Visual
[Mh] Termos MeSH secundário: Idoso
Inibidores da Angiogênese/administração & dosagem
Relação Dose-Resposta a Droga
Implantes de Medicamento
Quimioterapia Combinada
Feminino
Seguimentos
Glucocorticoides/administração & dosagem
Seres Humanos
Injeções Intravítreas
Edema Macular/diagnóstico
Edema Macular/etiologia
Masculino
Oclusão da Veia Retiniana/complicações
Oclusão da Veia Retiniana/diagnóstico
Estudos Retrospectivos
Fatores de Tempo
Tomografia de Coerência Óptica
Resultado do Tratamento
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Drug Implants); 0 (Glucocorticoids); 0 (Vascular Endothelial Growth Factor A); 7S5I7G3JQL (Dexamethasone); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1007/s00417-017-3852-1


  5 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320621
[Au] Autor:Karadzic J; Radosavljevic A; Kovacevic I
[Ti] Título:Central retinal vein occlusion: A patient with systemic sclerosis.
[So] Source:Vojnosanit Pregl;73(9):868-72, 2016 Sep.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Scleroderma (systemic sclerosis) is a severe chronic connective tissue disease, which results in involvement of numerous internal organs. Changes in the eye are the consequences of organ-specific manifestations of scleroderma or adverse effects of immunosuppressive treatment applied. Case report: We reported a 42-year-old woman with systemic sclerosis and acute deterioration of vision in the left eye, with visual acuity 0.9. After thorough clinical examination, including fluorescein angiography and optical coherence tomography, the diagnosis of nonischemic central retinal vein occlusion was made. Further biochemical, rheumatological and immunological investigation, apart from inactive systemic sclerosis, showed normal findings. Therefore, the cause of central retinal vein occlusion could only be attributed to the microvascular changes in systemic sclerosis. After three months, visual acuity deteriorated to 0.6 due to the development of cystoid macular edema. The patient received intravitreal injection of bevacizumab and after a single dose visual acuity improved to 0.9. After a 6- month follow-up, macular edema resolved and visual acuity stabilized. Conclusion: According to our knowledge and current data from the literature, central retinal vein occlusion is a rare vision threatening manifestation of scleroderma. There are only few published case reports on central vein occlusion in scleroderma patients. Examination of the ocular fundus is recommended for evaluation of vascular disease in patients with systemic sclerosis.
[Mh] Termos MeSH primário: Oclusão da Veia Retiniana/etiologia
Escleroderma Sistêmico/complicações
[Mh] Termos MeSH secundário: Adulto
Bevacizumab/administração & dosagem
Feminino
Angiofluoresceinografia
Seres Humanos
Injeções Intravítreas
Edema Macular/etiologia
Edema Macular/fisiopatologia
Fotografia
Recuperação de Função Fisiológica
Oclusão da Veia Retiniana/diagnóstico por imagem
Oclusão da Veia Retiniana/tratamento farmacológico
Oclusão da Veia Retiniana/fisiopatologia
Escleroderma Sistêmico/diagnóstico
Escleroderma Sistêmico/tratamento farmacológico
Tomografia de Coerência Óptica
Resultado do Tratamento
Transtornos da Visão/etiologia
Transtornos da Visão/fisiopatologia
Acuidade Visual
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
2S9ZZM9Q9V (Bevacizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.2298/VSP141028073K


  6 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470332
[Au] Autor:Jeppesen SK; Bek T
[Ad] Endereço:Department of Ophthalmology, Aarhus University Hospital, Aarhus C, Denmark.
[Ti] Título:Retinal Oxygen Saturation Correlates With Visual Acuity but Does Not Predict Outcome After Anti-VEGF Treatment in Central Retinal Vein Occlusion.
[So] Source:Invest Ophthalmol Vis Sci;58(5):2498-2502, 2017 05 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: Occlusion of the central retinal vein (CRVO) is a frequent cause of visual loss. The occlusion induces hypoxia in the retina and the larger retinal veins, but the significance of retinal oxygen saturation for visual acuity at diagnosis and after anti-VEGF treatment for CRVO has not been studied in detail. Methods: Retinal oximetry was performed in 91 patients consecutively referred for specialist evaluation of CRVO. The correlation between oxygen saturation in larger retinal vessels and visual acuity at the primary examination and the predictive value of oxygen saturation for visual prognosis after three monthly intravitreal injections with anti-VEGF medication were studied. Results: At referral, the oxygen saturation in larger retinal vessels of the affected eye was significantly higher in arterioles (100.7 ± 1.4% vs. 96.3 ± 0.6%) and significantly lower in venules (37.8 ± 2.6% vs. 58.2 ± 1.3%) than in the unaffected eye (P < 0.001 for both comparisons). Best-corrected visual acuity (BCVA) showed a significant negative correlation with the oxygen saturation in retinal arterioles (P = 0.002) and a significant positive correlation with the saturation in retinal venules (P = 0.013). Multiple linear regression showed that BCVA, but not oxygen saturations, contributed significantly to predicting visual outcome after three monthly intravitreal injections with VEGF inhibitor. Conclusions: The correlation between retinal oxygen saturation and BCVA at the time of diagnosis of CRVO may help understanding hemodynamic and visual changes in the acute stages of the disease. However, retinal oximetry cannot replace measures of retinal function as a predictive parameter for the visual outcome in CRVO after three monthly intravitreal anti-VEGF injections.
[Mh] Termos MeSH primário: Oxigênio/metabolismo
Ranibizumab/administração & dosagem
Receptores de Fatores de Crescimento do Endotélio Vascular/administração & dosagem
Proteínas Recombinantes de Fusão/administração & dosagem
Oclusão da Veia Retiniana/metabolismo
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
Acuidade Visual
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Inibidores da Angiogênese/administração & dosagem
Feminino
Seguimentos
Seres Humanos
Injeções Intravítreas
Masculino
Meia-Idade
Oximetria
Oclusão da Veia Retiniana/tratamento farmacológico
Oclusão da Veia Retiniana/fisiopatologia
Vasos Retinianos
Estudos Retrospectivos
Tomografia de Coerência Óptica
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Recombinant Fusion Proteins); 0 (Vascular Endothelial Growth Factor A); 15C2VL427D (aflibercept); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor); S88TT14065 (Oxygen); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180124
[Lr] Data última revisão:
180124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-21532


  7 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452939
[Au] Autor:Cehofski LJ; Honoré B; Vorum H
[Ad] Endereço:Department of Ophthalmology, Aalborg University Hospital, Hobrovej 18-22, 9000 Aalborg, Denmark. L.cehofski@rn.dk.
[Ti] Título:A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.
[So] Source:Int J Mol Sci;18(5), 2017 Apr 28.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR) and age-related macular degeneration (AMD) are frequent ocular diseases with potentially sight-threatening outcomes. In the present review we discuss major findings of proteomic studies of RAO, RVO, DR and AMD, including an overview of ocular proteome changes associated with anti-vascular endothelial growth factor (VEGF) treatments. Despite the severe outcomes of RAO, the proteome of the disease remains largely unstudied. There is also limited knowledge about the proteome of RVO, but proteomic studies suggest that RVO is associated with remodeling of the extracellular matrix and adhesion processes. Proteomic studies of DR have resulted in the identification of potential therapeutic targets such as carbonic anhydrase-I. Proliferative diabetic retinopathy is the most intensively studied stage of DR. Proteomic studies have established VEGF, pigment epithelium-derived factor (PEDF) and complement components as key factors associated with AMD. The aim of this review is to highlight the major milestones in proteomics in RAO, RVO, DR and AMD. Through large-scale protein analyses, proteomics is bringing new important insights into these complex pathological conditions.
[Mh] Termos MeSH primário: Retinopatia Diabética/patologia
Degeneração Macular/patologia
Proteoma/análise
Proteômica
Oclusão da Artéria Retiniana/patologia
Oclusão da Veia Retiniana/patologia
[Mh] Termos MeSH secundário: Anticorpos/imunologia
Anticorpos/uso terapêutico
Retinopatia Diabética/tratamento farmacológico
Retinopatia Diabética/metabolismo
Proteínas do Olho/metabolismo
Seres Humanos
Degeneração Macular/tratamento farmacológico
Degeneração Macular/metabolismo
Fatores de Crescimento Neural/metabolismo
Oclusão da Artéria Retiniana/tratamento farmacológico
Oclusão da Artéria Retiniana/metabolismo
Oclusão da Veia Retiniana/tratamento farmacológico
Oclusão da Veia Retiniana/metabolismo
Serpinas/metabolismo
Fator A de Crescimento do Endotélio Vascular/imunologia
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies); 0 (Eye Proteins); 0 (Nerve Growth Factors); 0 (Proteome); 0 (Serpins); 0 (Vascular Endothelial Growth Factor A); 0 (pigment epithelium-derived factor)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180122
[Lr] Data última revisão:
180122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  8 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29204993
[Au] Autor:Jiang Y; Mieler WF
[Ad] Endereço:University of Illinois at Chicago, Chicago, IL, United States.
[Ti] Título:Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions.
[So] Source:Asia Pac J Ophthalmol (Phila);6(6):546-553, 2017 Nov-Dec.
[Is] ISSN:2162-0989
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:The use of anti-vascular endothelial growth factor (VEGF) therapy in ophthalmology has profoundly changed our management and treatment of conditions such as cystoid macular edema, diabetic macular edema, choroidal neovascularization, and other proliferative retinopathies. Although initially used for the treatment of choroidal neovascularization in neovascular age-related macular degeneration, their application has spread rapidly for other indications as their outcomes have often outperformed previously existing treatments. Retinal vein occlusion (RVO) continues to be one of the leading causes of vision loss secondary to macular edema, in addition to macular ischemia and neovascularization in more severe cases. Before the availability of anti-VEGF therapy, the use of macular grid laser and panretinal photocoagulation was the mainstay of treatment of macular edema and neovascularization, respectively, in patients with RVOs. Two landmarks studies established the guidelines of these treatments for nearly a quarter century. Since the availability of anti-VEGF agents, there has been a paradigm shift in the treatment of RVO. Most importantly, there has also been a significant improvement in visual outcomes in these patients. The goal of this article is to provide a review of the pertinent clinical studies that have investigated the use of anti-VEGF in patients with retinal vein occlusions.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Oclusão da Veia Retiniana/tratamento farmacológico
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Bevacizumab/uso terapêutico
Ensaios Clínicos como Assunto
Seres Humanos
Injeções Intravítreas
Edema Macular/tratamento farmacológico
Ranibizumab/uso terapêutico
Receptores de Fatores de Crescimento do Endotélio Vascular/uso terapêutico
Proteínas Recombinantes de Fusão/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Angiogenesis Inhibitors); 0 (Recombinant Fusion Proteins); 0 (Vascular Endothelial Growth Factor A); 15C2VL427D (aflibercept); 2S9ZZM9Q9V (Bevacizumab); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.22608/APO.2017459


  9 / 3590 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29222552
[Au] Autor:Khayat M; Lois N; Williams M; Stitt AW
[Ad] Endereço:Wellcome-Wolfson Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, United Kingdom.
[Ti] Título:Animal Models of Retinal Vein Occlusion.
[So] Source:Invest Ophthalmol Vis Sci;58(14):6175-6192, 2017 Dec 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: To provide a comprehensive and current review on the available experimental animal models of retinal vein occlusion (RVO) and to identify their strengths and limitations with the purpose of helping researchers to plan preclinical studies on RVO. Methods: A systematic review of the literature on experimental animal models of RVO was undertaken. Medline, SCOPUS, and Web of Science databases were searched. Studies published between January 1, 1965, and March 31, 2017, and that met the inclusion criteria were reviewed. The data extracted included animal species used, methods of inducing RVO, and the clinical and histopathologic features of the models, especially in relation to strengths, limitations, and faithfulness to clinical sequelae. Results: A total of 128 articles fulfilling the inclusion criteria were included. Several species were used to model human branch and central RVO (BRVO; CRVO) with nonhuman primates being the most common, followed by rodents and pigs. BRVO and CRVO were most commonly induced by laser photocoagulation and all models showed early features of clinical disease, including retinal hemorrhages and retinal edema. These features made many of the models adequate for studying the acute phase of BRVO and CRVO, although macular edema, retinal ischemia, and neovascular complications were observed in only a few experimental animal models (laser-induced model in rodents, pigs, and nonhuman primates, diathermy-induced model in pigs, and following intravitreal injection of PD0325901 in rabbits for BRVO; and in the laser-induced model in rodents, rabbits, and nonhuman primates, diathermy-induced model in nonhuman primates, following permanent ligation of the central retinal vein in nonhuman primates, and with intravitreal injection of thrombin in rabbits for CRVO). Conclusions: Experimental animal models of RVO are available to study the pathogenesis of this disease and to evaluate diagnostic/prognostic biomarkers and to develop new therapeutics. Data available suggest laser-induced RVO in pigs and rodents to be overall the best models of BRVO and the laser-induced RVO rodents the best model for CRVO.
[Mh] Termos MeSH primário: Oclusão da Veia Retiniana/diagnóstico
Acuidade Visual
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171215
[Lr] Data última revisão:
171215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171210
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22788


  10 / 3590 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29183041
[Au] Autor:Hwang HS; Chae JB; Kim JY; Kim DY
[Ad] Endereço:Department of Ophthalmology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
[Ti] Título:Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
[So] Source:Invest Ophthalmol Vis Sci;58(13):5958-5967, 2017 Nov 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: To investigate the association between hyperreflective dots (HRDs) on spectral-domain optical coherence tomography (SD-OCT) and response to intravitreal bevacizumab (IVB) or dexamethasone injection in eyes with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO). Methods: A retrospective review was conducted involving patients with DME or macular edema due to RVO. Patients with treatment-naïve macular edema were initially treated with three consecutive IVB injections and classified based on the treatment response to bevacizumab. After three consecutive IVB injections, bevacizumab nonresponders were treated using dexamethasone implants and reclassified based on the treatment response. The best-corrected visual acuity, number of HRDs, and outer plexiform layer (OPL) disruptions were analyzed according to the treatment response. Results: Eighty-two eyes with DME and 68 eyes with RVO were included in this study. Thirty-six (43.9%) eyes with DME and 22 (32.4%) eyes with RVO were bevacizumab nonresponders. The number of baseline HRDs in bevacizumab nonresponders (16.06 ± 6.60 in DME, 14.23 ± 4.09 in RVO) was significantly greater than that in responders (11.26 ± 3.64, P < 0.001 in DME, 11.17 ± 4.83, P = 0.013 in RVO), and it did not decrease after IVB injections. Unlike the response to bevacizumab, eyes that responded to dexamethasone implant but not to IVB had significantly more HRDs (19.56 ± 6.75) than eyes that did not respond (11.50 ± 3.78, P = 0.006). The OPL disruption rate was significantly higher in bevacizumab nonresponders than in responders (P < 0.001 in DME and P = 0.001 in RVO). Conclusions: In patients with DME or macular edema due to RVO, the number of HRDs on SD-OCT may be a predictive indicator of the response to IVB injection or dexamethasone implant. In bevacizumab responders, the number of HRDs on SD-OCT was small. In contrast, more HRDs, which might reflect increased inflammation in the retina, were observed in dexamethasone responders. Therefore, dexamethasone implants might be more effective in DME or RVO eyes with multiple HRDs and OPL disruption on SD-OCT.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Anti-Inflamatórios/uso terapêutico
Bevacizumab/uso terapêutico
Dexametasona/uso terapêutico
Edema Macular/tratamento farmacológico
Edema Macular/patologia
Tomografia de Coerência Óptica/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Retinopatia Diabética/complicações
Feminino
Seres Humanos
Injeções Intravítreas
Edema Macular/diagnóstico por imagem
Masculino
Meia-Idade
Oclusão da Veia Retiniana/complicações
Estudos Retrospectivos
Acuidade Visual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Anti-Inflammatory Agents); 2S9ZZM9Q9V (Bevacizumab); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22725



página 1 de 359 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde